Implications of non-vitamin K antagonist oral anticoagulant trials in ablation practice.

19 March 2019 (13:05 - 13:20)

Organised by:

About the speaker

Doctor Massimo Grimaldi

Regional General Hospital F. Miulli, Acquaviva Delle Fonti (Italy)

4 More presentations in this session

Presentation thumbnail

Welcome and Introduction - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Professor S. Hohnloser (Frankfurt, DE)

Presentation thumbnail

ELIMINATE-AF trial in the context of other non-vitamin K antagonist oral anticoagulant trials.

Professor J. Kautzner (Prague, CZ)

Presentation thumbnail

Current recommendation for atrial fibrillation patients undergoing ablation.

Professor J. Steffel (Zurich, CH)

Presentation thumbnail

Panel discussion and closing remarks - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Professor S. Hohnloser (Frankfurt, DE)

Access the full session

Session thumbnail

Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

The Event

EHRA 2019

19 March 2019 13:05 CET

You may be interested in

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Presentation

State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope

Congress Session

Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources